Bakgrund
B1. American Psychiatric Association (2013): DSM-5 Textbook (Diagnostic and statistical manual of mental disorders. Fifth Edition). Arlington, VA, American Psychiatric Association.

B2. Herlofson, J (2015). Mini D 5. Diagnoskriterier enligt DSM-5. Svensk översättning. American Psychiatric Association (DSM-5, 2013). ISBN: 978-91-980079-1-6.

B3. Radomsky AS, Rachman S, Thordarson DS, McIsaac HK, Teachman BA (2001). The Claustrophobia Questionnaire. J Anxiety Disord. 15(4):287-97.

B4. Lourenco SF, Longo MR, Pathman T (2011). Near space and its relation to claustrophobic fear. Cognition. 119(3):448-53.

B5. Napp AE, Enders J, Roehle R, Diederichs G, Rief M, Zimmermann E, Martus P, Dewey M (2017). Analysis and Prediction of Claustrophobia during MR Imaging with the Claustrophobia Questionnaire: An Observational Prospective 18-month Single-Center Study of 6500 Patients. Radiology. 283(1):148-157.

B6. Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC (1996). Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 53(2):159-68.

B7. Wikipedia (2020): https://en.wikipedia.org/wiki/Glossophobia

B8. Remes O, Brayne C, van der Linde R, Lafortune L (2016). A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav.  6(7):e00497.

B9. Bandelow B, Michaelis S (2015). Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 17(3):327-35.

B10. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 62(6): 593-602.

B11. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T (2013). Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 382(9904): 1575-86.

B12. Goldberg D, Fawcett J (2012). The importance of anxiety in both major depression and bipolar disorder. Depress Anxiety. 29(6): 471-8.

B13. Beard C, Moitra E, Weisberg RB, Keller MB (2010). Characteristics and predictors of social phobia course in a longitudinal study of primary-care patients. Depress Anxiety. 27(9):839-45.

B14. Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, Smith SM, Saha TD, Huang B (2005). Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 35(12):1747-59.

B15. Stein DJ, Lim CCW, Roest AM, de Jonge P, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Benjet C, Bromet EJ, Bruffaerts R, de Girolamo G, Florescu S, Gureje O, Haro JM, Harris MG, He Y, Hinkov H, Horiguchi I, Hu C, Karam A, Karam EG, Lee S, Lepine JP, Navarro-Mateu F, Pennell BE, Piazza M, Posada-Villa J, Ten Have M, Torres Y, Viana MC, Wojtyniak B, Xavier M, Kessler RC, Scott KM; WHO World Mental Health Survey Collaborators (2017). The cross-national epidemiology of social anxiety disorder: Data from the World Mental Health Survey Initiative. BMC Med. 15(1):143.

B16. Combs H, Markman J (2014). Anxiety disorders in primary care. Med Clin North Am. 98(5):1007-23

B17. Schutters SI, Dominguez MD, Knappe S, Lieb R, van Os J, Schruers KR, Wittchen HU (2012). The association between social phobia, social anxiety cognitions and paranoid symptoms. Acta Psychiatr Scand. 125(3):213-27.

B18. Merikangas KR, Avenevoli S, Acharyya S, Zhang H, Angst J (2002). The spectrum of social phobia in the Zurich cohort study of young adults. Biol Psychiatry. 51(1):81-91.

B19. Goldenberg IM, White K, Yonkers K, Reich J, Warshaw MG, Goisman RM, Keller MB (1996). The infrequency of "pure culture" diagnoses among the anxiety disorders. J Clin Psychiatry. 57(11):528-33.

B20. Torres AR, Ferrão YA, Shavitt RG, Diniz JB, Costa DL, do Rosário MC, Miguel EC, Fontenelle LF (2014). Panic Disorder and Agoraphobia in OCD patients: clinical profile and possible treatment implications. Compr Psychiatry. 55(3):588-97.

B21. Vázquez GH, Baldessarini RJ, Tondo L (2014). Co-occurrence of anxiety and bipolar disorders: clinical and therapeutic overview. Depress Anxiety. 31(3): 196-206.

B22. Perugi G, Akiskal HS, Toni C, Simonini E, Gemignani A (2001). The temporal relationship between anxiety disorders and (hypo)mania: a retrospective examination of 63 panic, social phobic and obsessive-compulsive patients with comorbid bipolar disorder. J Affect Disord. 67(1-3): 199-206.

B23. Yapici Eser H, Kacar AS, Kilciksiz CM, Yalçinay-Inan M, Ongur D (2018). Prevalence and Associated Features of Anxiety Disorder Comorbidity in Bipolar Disorder: A Meta-Analysis and Meta-Regression Study. Front Psychiatry. 9:229.

B24. Henriksson MM, Isometsä ET, Kuoppasalmi KI, Heikkinen ME, Marttunen MJ, Lönnqvist JK (1996). Panic disorder in completed suicide. J Clin Psychiatry. 57(7): 275-81.

B25. Chartrand H, Sareen J, Toews M, Bolton JM (2012). Suicide attempts versus nonsuicidal self-injury among individuals with anxiety disorders in a nationally representative sample. Depress Anxiety. 29(3):172-9.

B26. Stanley IH, Boffa JW, Rogers ML, Hom MA, Albanese BJ, Chu C, Capron DW, Schmidt NB, Joiner TE (2018). Anxiety sensitivity and suicidal ideation/suicide risk: A meta-analysis. J Consult Clin Psychol. 86(11):946-960.

B27. Tully PJ, Cosh SM, Baumeister H (2014). The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. 77(6): 439-48.

B28. Tully PJ, Harrison NJ, Cheung P, Cosh S (2016). Anxiety and Cardiovascular Disease Risk: a Review. Curr Cardiol Rep. 18(12):120.

B29. Sandström YK, Ljunggren G, Wändell P, Wahlström L, Carlsson AC (2016). Psychiatric comorbidities in patients with hypertension - a study of registered diagnoses 2009-2013 in the total population in Stockholm County, Sweden. J Hypertens. 34(3): 414-20.

B30. Johnson HM (2019). Anxiety and Hypertension: Is There a Link? A Literature Review of the Comorbidity Relationship Between Anxiety and Hypertension. Curr Hypertens Rep. 21(9):66.

B31. Panagioti M, Scott C, Blakemore A, Coventry PA (2014). Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 9:1289-306.

B32. Stojanović-Tasić M, Grgurević A, Cvetković J, Grgurević U, Trajković G (2014). Association between somatic diseases and symptoms of depression and anxiety among Belgrade University students. Med Glas (Zenica). 11(2): 373-8.

B33. Fuller-Thomson E, Lateef R, Sulman J (2015). Robust Association Between Inflammatory Bowel Disease and Generalized Anxiety Disorder: Findings from a Nationally Representative Canadian Study. Inflamm Bowel Dis. 21(10):2341-8.

B34. Chaturvedi SK, Manche Gowda S, Ahmed HU, Alosaimi FD, Andreone N, Bobrov A, Bulgari V, Carrà G, Castelnuovo G, de Girolamo G, Gondek T, Jovanovic N, Kamala T, Kiejna A, Lalic N, Lecic-Tosevski D, Minhas F, Mutiso V, Ndetei D, Rabbani G, Somruk S, Srikanta S, Taj R, Valentini U, Vukovic O, Wölwer W, Cimino L, Nouwen A, Lloyd C, Sartorius N (2019). More anxious than depressed: prevalence and correlates in a 15-nation study of anxiety disorders in people with type 2 diabetes mellitus. Gen Psychiatr. 32(4):e100076.

B35. Ittermann T, Völzke H, Baumeister SE, Appel K, Grabe HJ (2015). Diagnosed thyroid disorders are associated with depression and anxiety. Soc Psychiatry Psychiatr Epidemiol. 50(9): 1417-25.

B36. Nehlig A (2016). Effects of coffee/caffeine on brain health and disease: What should I tell my patients? Pract Neurol. 16(2): 89-95.

B37. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, Hasin DS (2015). Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 72(8):757-66.

B38. Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J, Zhang H, Smith SM, Pickering RP, Huang B, Hasin DS (2016). Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry. 73(1):39-47.

B39. Alegría AA, Hasin DS, Nunes EV, Liu SM, Davies C, Grant BF, Blanco C (2010). Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 71(9):1187-95; quiz 1252-3.

B40. Schneier FR, Foose TE, Hasin DS, Heimberg RG, Liu SM, Grant BF, Blanco C (2010). Social anxiety disorder and alcohol use disorder co-morbidity in the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 40(6):977-88.

B41. Prior K, Mills K, Ross J, Teesson M (2017). Substance use disorders comorbid with mood and anxiety disorders in the Australian general population. Drug Alcohol Rev. 36(3):317-324.

B42. Vorspan F, Mehtelli W, Dupuy G, Bloch V, Lépine JP (2015). Anxiety and substance use disorders: co-occurrence and clinical issues. Curr Psychiatry Rep. 17(2): 4.

B43. Swendsen JD, Merikangas KR, Canino GJ, Kessler RC, Rubio-Stipec M, Angst J (1998). The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities. Compr Psychiatry. 39(4):176-84.

B44. Robinson J, Sareen J, Cox BJ, Bolton J (2009). Self-medication of anxiety disorders with alcohol and drugs: Results from a nationally representative sample. J Anxiety Disord. 23(1):38-45.

B45. Croen LA, Zerbo O, Qian Y, Massolo ML, Rich S, Sidney S, Kripke C (2015). The health status of adults on the autism spectrum. Autism. 19(7):814-23.

B46. Gordon-Lipkin E, Marvin AR, Law JK, Lipkin PH (2018). Anxiety and Mood Disorder in Children With Autism Spectrum Disorder and ADHD. Pediatrics. 141(4):e20171377.

B47. Hofvander B, Delorme R, Chaste P, Nydén A, Wentz E, Ståhlberg O, Herbrecht E, Stopin A, Anckarsäter H, Gillberg C, Råstam M, Leboyer M (2009). Psychiatric and psychosocial problems in adults with normal-intelligence autism spectrum disorders. BMC Psychiatry. 9:35.

B48. Schatz DB, Rostain AL (2006). ADHD with comorbid anxiety: a review of the current literature. J Atten Disord. 10(2): 141-9.

B49. Anastopoulos AD, DuPaul GJ, Weyandt LL, Morrissey-Kane E, Sommer JL, Rhoads LH, Murphy KR, Gormley MJ, Gudmundsdottir BG (2018). Rates and Patterns of Comorbidity Among First-Year College Students With ADHD. J Clin Child Adolesc Psychol. 47(2):236-247.

B50. Ung D, Wood JJ, Ehrenreich-May J, Arnold EB, Fuji C, Renno P, Murphy TK, Lewin AB, Mutch PJ, Storch EA (2013). Clinical characteristics of high-functioning youth with autism spectrum disorder and anxiety. Neuropsychiatry (London). 3(2).

B51. van Steensel FJ, Bögels SM, Perrin S (2011). Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. Clin Child Fam Psychol Rev. 14(3): 302-17.

B52. Kuusikko S, Pollock-Wurman R, Jussila K, Carter AS, Mattila ML, Ebeling H, Pauls DL, Moilanen I (2008). Social anxiety in high-functioning children and adolescents with Autism and Asperger syndrome. J Autism Dev Disord. 38(9):1697-709.

B53. Kuusikko-Gauffin S, Pollock-Wurman R, Mattila ML, Jussila K, Ebeling H, Pauls D, Moilanen I (2013). Social anxiety in parents of high-functioning children with autism and Asperger syndrome. J Autism Dev Disord. 43(3):521-9.

B54. Onur E, Alkın T, Sheridan MJ, Wise TN (2013). Alexithymia and emotional intelligence in patients with panic disorder, generalized anxiety disorder and major depressive disorder. Alexithymia and emotional intelligence in patients with panic disorder, generalized anxiety disorder and major depressive disorder. Psychiatr Q. 84(3): 303-11.

B55. Guttmann-Steinmetz S, Gadow KD, DeVincent CJ, Crowell J (2010). Anxiety symptoms in boys with autism spectrum disorder, attention-deficit hyperactivity disorder, or chronic multiple tic disorder and community controls. J Autism Dev Disord. 40(8): 1006-16.

B56. Lever AG, Geurts HM (2016). Psychiatric Co-occurring Symptoms and Disorders in Young, Middle-Aged, and Older Adults with Autism Spectrum Disorder. J Autism Dev Disord. 46(6): 1916-30.

B57. Herlofson J, Ekselius L (2016). [Personality disorders--description, definition and diagnosis]. Läkartidningen. 113:D4R7. Swedish.

B58. Cox BJ, Pagura J, Stein MB, Sareen J (2009). The relationship between generalized social phobia and avoidant personality disorder in a national mental health survey. Depress Anxiety. 26(4): 354-62.

B59. Reichborn-Kjennerud T, Czajkowski N, Torgersen S, Neale MC, Ørstavik RE, Tambs K, Kendler KS (2007). The relationship between avoidant personality disorder and social phobia: a population-based twin study. Am J Psychiatry. 164(11):1722-8.

B60. Rutgers AH, Bakermans-Kranenburg MJ, van Ijzendoorn MH, van Berckelaer-Onnes IA (2004). Autism and attachment: a meta-analytic review. J Child Psychol Psychiatry. 45(6):1123-34.

B61. Hengartner MP, von Wyl A, Tanis T, Halmi W, Galynker I, Cohen LJ (2015). Severity of personality disorders and domains of general personality dysfunction related to attachment. Personal Ment Health. 9(3):195-207.

B62. MacDonald K, Berlow R, Thomas ML (2013). Attachment, affective temperament, and personality disorders: a study of their relationships in psychiatric outpatients. J Affect Disord. 151(3): 932-41.

B63. Kampman O, Viikki M, Järventausta K, Leinonen E (2014). Meta-analysis of anxiety disorders and temperament. Neuropsychobiology. 69(3): 175-86.

B64. Kadak MT, Demirel ÖF, Gökalp B, Erdoğdu Z, Demirel A (2015). Relationship between temperament, character and the autistic trait in parents of children with autistic spectrum disorder. Int J Psychiatry Clin Pract. 19(3): 216-20.

B65. Karam EG, Salamoun MM, Yeretzian JS, Mneimneh ZN, Karam AN, Fayyad J, Hantouche E, Akiskal K, Akiskal HS (2010). The role of anxious and hyperthymic temperaments in mental disorders: a national epidemiologic study. World Psychiatry. 9(2): 103-10.

B66. Roy MA, Neale MC, Pedersen NL, Mathé AA, Kendler KS (1995). A twin study of generalized anxiety disorder and major depression. Psychol Med. 25(5):1037-49.

B67. Hettema JM, Prescott CA, Myers JM, Neale MC, Kendler KS (2005). The structure of genetic and environmental risk factors for anxiety disorders in men and women. Arch Gen Psychiatry. 62(2):182-9.

B68. Ogliari A, Spatola CA, Pesenti-Gritti P, Medda E, Penna L, Stazi MA, Battaglia M, Fagnani C (2010). The role of genes and environment in shaping co-occurrence of DSM-IV defined anxiety dimensions among Italian twins aged 8-17. J Anxiety Disord. 2010 May;24(4):433-9.

B69. Hellwig S, Domschke K (2019). Anxiety in Late Life: An Update on Pathomechanisms. Gerontology. 65(5):465-473.

B70. Foell J, Palumbo IM, Yancey JR, Vizueta N, Demirakca T, Patrick CJ (2019). Biobehavioral threat sensitivity and amygdala volume: A twin neuroimaging study. Neuroimage. 186:14-21.

B71. Bach DR, Hoffmann M, Finke C, Hurlemann R, Ploner CJ (2019). Disentangling Hippocampal and Amygdala Contribution to Human Anxiety-Like Behavior. J Neurosci. 39(43):8517-8526.

B72. Indovina I, Robbins TW, Núñez-Elizalde AO, Dunn BD, Bishop SJ (2011). Fear-conditioning mechanisms associated with trait vulnerability to anxiety in humans. Neuron. 69(3):563-71.

B73. Zidda F, Andoh J, Pohlack S, Winkelmann T, Dinu-Biringer R, Cavalli J, Ruttorf M, Nees F, Flor H (2018). Default mode network connectivity of fear- and anxiety-related cue and context conditioning. Neuroimage. 165:190-199.

B74. Faria V, Ahs F, Appel L, Linnman C, Bani M, Bettica P, Pich EM, Wahlstedt K, Fredrikson M, Furmark T (2014). Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder. Int J Neuropsychopharmacol. 17(8):1149-57.

B75. Hollander E, Braun A, Simeon D (2008). Should OCD leave the anxiety disorders in DSM-V? The case for obsessive compulsive-related disorders. Depress Anxiety. 25(4):317-29.

B76. Marras A, Fineberg N, Pallanti S (2016). Obsessive compulsive and related disorders: comparing DSM-5 and ICD-11. CNS Spectr. 21(4):324-33.

B77. Zilhão NR, Smit DJ, Boomsma DI, Cath DC (2016). Cross-Disorder Genetic Analysis of Tic Disorders, Obsessive-Compulsive, and Hoarding Symptoms. Front Psychiatry. 7:120.

B78. Sheppard B, Chavira D, Azzam A, Grados MA, Umaña P, Garrido H, Mathews CA (2010). ADHD prevalence and association with hoarding behaviors in childhood-onset OCD. Depress Anxiety. 27(7):667-74.

B79. Bienvenu OJ, Samuels JF, Riddle MA, Hoehn-Saric R, Liang KY, Cullen BA, Grados MA, Nestadt G (2000). The relationship of obsessive-compulsive disorder to possible spectrum disorders: results from a family study. Biol Psychiatry. 48(4):287-93.

B80. Özyurt G, Beşiroğlu L (2018). Autism Spectrum Symptoms in Children and Adolescents with Obsessive Compulsive Disorder and Their Mothers. Noro Psikiyatr Ars. 55(1):40-48.

B81. Wikramanayake WNM, Mandy W, Shahper S, Kaur S, Kolli S, Osman S, Reid J, Jefferies-Sewell K, Fineberg NA (2018). Autism spectrum disorders in adult outpatients with obsessive compulsive disorder in the UK. Int J Psychiatry Clin Pract. 22(1):54-62.

B82. van Grootheest DS, Cath DC, Beekman AT, Boomsma DI (2005). Twin studies on obsessive-compulsive disorder: a review. Twin Res Hum Genet. 8(5):450-8.

B83. Clifford CA, Murray RM, Fulker DW (1984). Genetic and environmental influences on obsessional traits and symptoms. Psychol Med. 14(4):791-800.

B84. Hur YM, Jeong HU (2008). Sex differences in genetic and environmental influences on obsessive-compulsive symptoms in South Korean adolescent and young adult twins. Twin Res Hum Genet. 11(3):314-20.

B85. Oe M, Ito M, Takebayashi Y, Katayanagi A, Horikoshi M (2020). Prevalence and comorbidity of the ICD-11 and DSM-5 for PTSD caseness with previous diagnostic manuals among the Japanese population. Eur J Psychotraumatol. 11(1):1753938.

B86. Löwe B, Kroenke K, Spitzer RL, Williams JB, Mussell M, Rose M, Wingenfeld K, Sauer N, Spitzer C (2011). Trauma exposure and posttraumatic stress disorder in primary care patients: cross-sectional criterion standard study. J Clin Psychiatry. 72(3):304-12.

B87. Spinhoven P, Penninx BW, van Hemert AM, de Rooij M, Elzinga BM (2014). Comorbidity of PTSD in anxiety and depressive disorders: prevalence and shared risk factors. Child Abuse Negl. 38(8):1320-30.

B88. Wolf EJ, Mitchell KS, Koenen KC, Miller MW (2014). Combat exposure severity as a moderator of genetic and environmental liability to post-traumatic stress disorder. Psychol Med. 44(7):1499-509.

B89. Wolf EJ, Miller MW, Sullivan DR, Amstadter AB, Mitchell KS, Goldberg J, Magruder KM (2018). A classical twin study of PTSD symptoms and resilience: Evidence for a single spectrum of vulnerability to traumatic stress. Depress Anxiety. 35(2):132-139.

B90. Kremen WS, Koenen KC, Afari N, Lyons MJ (2012). Twin studies of posttraumatic stress disorder: differentiating vulnerability factors from sequelae. Neuropharmacology. 62(2):647-53.

B91. WHO (1992). ICD-10 (International classification of diseases for mortality and morbidity statistics, 10th Revision). World Health Organization.

B92. WHO (2018). ICD-11 (International classification of diseases for mortality and morbidity statistics, 11th Revision). World Health Organization. https://icd.who.int/browse11/l-m/en

B93. American Psychiatric Association (2000). Task force on DSM-IV: Diagnostic and statistical manual of mental disorders. 4:e uppl. Washington, DC: American Psychiatric Association.

B94. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 61(8): 807-16.

B95. Weaver T, Madden P, Charles V, Stimson G, Renton A, Tyrer P, Barnes T, Bench C, Middleton H, Wright N, Paterson S, Shanahan W, Seivewright N, Ford C; Comorbidity of Substance Misuse and Mental Illness Collaborative study team (2003). Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry. 183:304-13.

B96. Hoch E, Bonnetn U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss UW (2015). Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int. 112(16): 271-8.

B97. Mihic SJ, Kalant H, Liu JF, Wu PH (1992). Role of the gamma-aminobutyric acid receptor/chloride channel complex in tolerance to ethanol and cross-tolerance to diazepam and pentobarbital. J Pharmacol Exp Ther. 1992 Apr;261(1):108-13.

B98. Volavka J, Verebey K, Resnick R, Mulé S (1978). Methadone dose, plasma level, and cross-tolerance to heroin in man. J Nerv Ment Dis. 166(2): 104-9.

B99. Pava MJ, Woodward JJ (2012). A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. Alcohol. 46(3): 185-204.

B100. Goldstein BI, Levitt AJ (2006). Factors associated with temporal priority in comorbid bipolar I disorder and alcohol use disorders: Results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 67(4): 643-9.

B101. Angst J, Gamma A, Endrass J, Rössler W, Ajdacic-Gross V, Eich D, Herrell R, Merikangas KR (2006). Is the association of alcohol use disorders with major depressive disorder a consequence of undiagnosed bipolar-II disorder? Eur Arch Psychiatry Clin Neurosci. 256(7): 452-7.

Utredning
C1. Zigmond SA, Snaith RP (1983). The hospital anxiety and depression scale. Acta Psychiatr Scand. 67(6). 361-70.

C2. Lisspers J, Nygren A, Soderman E (1997). Hospital anxiety and depression scale (HAD): some psychometric data for a Swedish sample. Acta Psychiatr Scand. 96(4): 281-86.

C3. Stern AF (2014). The hospital anxiety and depression scale. Occup Med (Lond). Jul;64(5):393-4.

C4. Bejerot S, Edman G, Anckarsäter H, Berglund G, Gillberg C, Hofvander B, Humble MB, Mörtberg E, Råstam M, Ståhlberg O, Frisén L (2014). The Brief Obsessive-Compulsive Scale (BOCS): a self-report scale for OCD and obsessive-compulsive related disorders. Nord J Psychiatry. 68(8):549-59.

C5. Wennberg P, Källmén H, Hermansson U, Bergman H (2008). AUDIT (Alcohol Use Disorders Identification Test) – svensk manual.

C6. Berman AH, Bergman H, Palmstierna T, Schlyter F (2007). DUDIT (Drug Use Disorders Identification Test) – svensk manual.

Behandling, uppföljning
D1. SBU (2005). Behandling av ångestsyndrom. SBU rapport. 171/1+2.

D2. Läkemedelsverket (2006). Farmakoterapi vid ångest – Behandlingsrekommendation. Information från Läkemedelsverket. 4

D3. FASS (2020): https://www.fass.se/LIF/startpage?userType=0

D4. Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D (2015). Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 30(4):183-92.

D5. Skapinakis P, Caldwell DM, Hollingworth W, Bryden P, Fineberg NA, Salkovskis P, Welton NJ, Baxter H, Kessler D, Churchill R, Lewis G (2016). Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 3(8):730-739.

D6. Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ (2013). Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 74(6):e541-50.

D7. Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, van Ommeren M, de Jong J, Seedat S, Chen H, Bisson JI (2015). Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry. 206(2):93-100.

D8. Romanelli RJ, Wu FM, Gamba R, Mojtabai R, Segal JB (2014). Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials. Depress Anxiety. 31(8):641-52.

D9. Del Casale A, Sorice S, Padovano A, Simmaco M, Ferracuti S, Lamis DA, Rapinesi C, Sani G, Girardi P, Kotzalidis GD, Pompili M (2019). Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD). Curr Neuropharmacol. 17(8):710-736.

D10. Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS (2007). Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry. 40(4):152-6.

D11. Mochcovitch MD, Nardi AE (2010). Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies. Expert Rev Neurother. 10(8):1285-93.

D12. Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K (2006). Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 67(6):874-81.

D13. Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N (2019). Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 393(10173):768-777.

D14. Serretti A, Mandelli L (2010). Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 71(10):1259-72.

D15. Fukui H, Murai T (2002). Severe weight gain induced by combination treatment with risperidone and paroxetine. Clin Neuropharmacol. 25(5):269-71.

D16. Maina G, Albert U, Salvi V, Bogetto F (2004). Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry. 65(10):1365-71.

D17. Bérard A, Zhao JP, Sheehy O (2017). Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open. 7(1):e013372.

D18. Bérard A, Iessa N, Chaabane S, Muanda FT, Boukhris T, Zhao JP (2016). The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis. Br J Clin Pharmacol. 81(4):589-604.

D19. Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y (2007). A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 194(2):233-42.

D20. Bose A, Korotzer A, Gommoll C, Li D (2008). Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety. 25(10):854-61.

D21. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM (2005). Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 177(3):280-8.

D22. Ball S, Marangell LB, Lipsius S, Russell JM (2013). Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 43:217-21.

D23. Nicolini H, Bakish D, Duenas H, Spann M, Erickson J, Hallberg C, Ball S, Sagman D, Russell JM (2009). Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med. 39(2): 267-76.

D24. Cipriani A, Williams T, Nikolakopoulou A, Salanti G, Chaimani A, Ipser J, Cowen PJ, Geddes JR, Stein DJ (2018). Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 48(12):1975-1984.

D25. Shulman KI, Herrmann N, Walker SE (2013). Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 27(10):789-97.

D26. Drugbank: https://www.drugbank.ca/drugs/DB00780

D27. Opatrny L, Delaney JA, Suissa S (2008). Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol. 66(1):76-81.

D28. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ (2010). Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 9(2):167-76.

D29. Hackam DG, Mrkobrada M (2012). Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 79(18):1862-5.

D30. Aarts N, Akoudad S, Noordam R, Hofman A, Ikram MA, Stricker BH, Visser LE, Vernooij MW (2014). Inhibition of serotonin reuptake by antidepressants and cerebral microbleeds in the general population. Stroke. 45(7):1951-7.

D31. Kim S, Ko YJ, Park K, Yang BR, Kim MS, Park BJ (2019). Fluoxetine and Risk of Bleeding in Patients Aged 60 Years and Older Using the Korea Adverse Event Reporting System Database: A Case/Noncase Study. J Clin Psychopharmacol. 39(4):362-366.

D32. He Y, Cai Z, Zeng S, Chen S, Tang B, Liang Y, Chang X, Guo Y (2018). Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study. Clin Neurol Neurosurg. 168:1-6.

D33. AFFINITY Trial Collaboration (2020). Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 19(8):651-660.

D34. KELLY HG, FAY JE, LAVERTY SG (1963). THIORIDAZINE HYDROCHLORIDE (MELLARIL): ITS EFFECT ON THE ELECTROCARDIOGRAM AND A REPORT OF TWO FATALITIES WITH ELECTROCARDIOGRAPHIC ABNORMALITIES. Can Med Assoc J. 89(11):546-54.

D35. Hennessy S, Bilker WB, Knauss JS, Kimmel SE, Margolis DJ, Morrison MF, Reynolds RF, Glasser DB, Strom BL (2004). Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol. Br J Clin Pharmacol. 58(1):81-7.

D36. Lester RM, Paglialunga S, Johnson IA (2019). QT Assessment in Early Drug Development: The Long and the Short of It. Int J Mol Sci. 20(6):1324.

D37. Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S (2011). Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf. 20(9):903-13.

D38. Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, Huffman JC (2018). QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 59(2):105-122.

D39. Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, Montastruc F, Montastruc JL (2017). A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology (Berl). 234(20):3075-3081.

D40. Wu WT, Tsai CT, Chou YC, Ku PM, Chen YC, You SL, Hung CF, Sun CA (2019). Cardiovascular Outcomes Associated With Clinical Use of Citalopram and Omeprazole: A Nationwide Population-Based Cohort Study. J Am Heart Assoc. 8(20):e011607.

D41. Schlit AF, Delaunois A, Colomar A, Claudio B, Cariolato L, Boev R, Valentin JP, Peters C, Sloan VS, Bentz JWG (2017). Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug. Pharmacol Res Perspect. 5(3):e00309.

D42. Sasson Y, Iancu I, Fux M, Taub M, Dannon PN, Zohar J (1999). A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol. 9(3): 191-6.

D43. Perna G, Daccò S, Menotti R, Caldirola D (2011). Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition. Neuropsychiatr Dis Treat. 7:621-37.

D44. Eriksson T (2018). Läkemedelsberoende (klinisk handbok om smärtstillande, lugnande och sömnmedel): https://www.akademiska.se/contentassets/8abcf46c866743a28c0f4471c799ab71/klinisk-handbok-lakemedelsberoende-18-01-03.pdf

D45. Sheehan DV (1987). Benzodiazepines in panic disorder and agoraphobia. J Affect Disord. 13: 169-181.

D46. Breilmann J, Girlanda F, Guaiana G, Barbui C, Cipriani A, Castellazzi M, Bighelli I, Davies SJ, Furukawa TA, Koesters M (2019). Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 3(3):CD010677.

D47. Moylan S, Staples J, Ward SA, Rogerson J, Stein DJ, Berk M (2011). The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol. 31(5): 647-52.

D48. Nardi AE, Valença AM, Freire RC, Mochcovitch MD, Amrein R, Sardinha A, Levitan MN, Nascimento I, de-Melo-Neto VL, King AL, de O E Silva AC, Veras AB, Dias GP, Soares-Filho GL, da Costa RT, Mezzasalma MA, de Carvalho MR, de Cerqueira AC, Hallak JE, Crippa JA, Versiani M (2011). Psychopharmacotherapy of panic disorder: 8-week randomized trial with clonazepam and paroxetine. Braz J Med Biol Res. 44(4):366-73.

D49. Freire RC, Amrein R, Mochcovitch MD, Dias GP, Machado S, Versiani M, Arias-Carrión O, Carta MG, Nardi AE (2017). A 6-Year Posttreatment Follow-up of Panic Disorder Patients: Treatment With Clonazepam Predicts Lower Recurrence Than Treatment With Paroxetine. J Clin Psychopharmacol. 37(4):429-434.

D50. Lader M (2011). Benzodiazepines revisited--will we ever learn? Addiction. 106(12):2086-109.

D51. Lader M, Kyriacou A (2016). Withdrawing Benzodiazepines in Patients With Anxiety Disorders. Curr Psychiatry Rep. 18(1): 8.

D52. Howland RH (2016). Safety and Abuse Liability of Oxazepam: Is This Benzodiazepine Drug Underutilized? J Psychosoc Nurs Ment Health Serv. 54(4):22-5.

D53. Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P (2017). Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 32(1):49-55.

D54. Williams T, McCaul M, Schwarzer G, Cipriani A, Stein DJ, Ipser J (2020). Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis. Acta Neuropsychiatr. 32(4):169-176.

D55. Baniasadi M, Hosseini G, Fayyazi Bordbar MR, Rezaei Ardani A, Mostafavi Toroghi H (2014). Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. J Psychiatr Pract. 20(6):419-27.

D56. Schjerning O, Rosenzweig M, Pottegård A, Damkier P, Nielsen J (2016). Abuse Potential of Pregabalin: A Systematic Review. CNS Drugs. 30(1): 9-25.

D57. Evoy KE, Morrison MD, Saklad SR (2017). Abuse and Misuse of Pregabalin and Gabapentin. Drugs. 77(4):403-426.

D58. Jansen K, Haugen DF, Pont L, Ruths S (2018). Safety and Effectiveness of Palliative Drug Treatment in the Last Days of Life-A Systematic Literature Review. J Pain Symptom Manage. 55(2):508-521.e3.

D59. Region Stockholms läkemedelskommitté (2020). Kloka Listan. Psykiatri.

D60. Läkemedelsrådet i Region Skåne (2020). Skånelistan. Psykiatri.

D61. SBU (2001). Behandling av alkohol- och narkotikaproblem. SBU-rapport. Rapportnr: 156 (2 vol).

D62. Läkemedelsindustriföreningen (2020). FASS. http://www.fass.se/LIF/startpage?userType=0
Läkemedelsverket (2015). Nya rekommendationer för att minska risk för hjärtbiverkningar med hydroxizin.

Bakgrund, Utredning, Behandling, Uppföljning
B-E1. Läkemedelsverket (2014). Läkemedelsboken (LB). Psykiatri. Ångest och oro. 1022-1037, och LB på nätet (tom början av 2016): http://www.lakemedelsboken.se/kapitel/psykiatri/angest_och_oro.html

Läkemedelsverket (2014). Läkemedelsboken (LB). Beroendetillstånd, 1101-48, och LB på nätet (tom början av 2016), http://lakemedelsboken.se/kapitel/beroendetillstand/tobaksberoende.html